Globus Medical Inc. (GMED)
Should You Hold Globus Medical Stock in Your Portfolio Now?
GMED stays on investors' radar due to its high NuVasive-merger synergies and solid Musculoskeletal prospects.
New Product Launches Benefit GMED Stock Amid Macro Issues
Globus Medical currently awaits a strong cadence of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.
Globus Medical Expands Anterior Spine Portfolio With Two New Offerings
GMED announces the commercial launch of COHERE ALIF Spacer and Modulus ALIF Blades.
Is the Options Market Predicting a Spike in Globus Medical (GMED) Stock?
Investors need to pay close attention to Globus Medical (GMED) stock based on the movements in the options market lately.
Globus Medical Q4 Earnings & Revenues Top, Margins Expand, Stock Dips
GMED's fourth-quarter 2024 performance reflects strong synergies from the NuVasive merger.
Globus Medical, Inc. (GMED) Q4 2024 Earnings Call Transcript
Globus Medical, Inc. (NYSE:GMED ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Brian Kearns - SVP, Business Development and IR Daniel Scavilla - President and CEO Keith Pfeil - COO and CFO Conference Call Participants Vik Chopra - Wells Fargo Matt Miksic - Barclays David Saxon - Needham & Company Jason Wittes - ROTH Shagun Singh - RBC Caitlin Cronin - Canaccord Genuity Craig Bijou - Bank of America Securities Matthew O'Brien - Piper Sandler Steve Lichtman - Oppenheimer Ryan Zimmerman - BTIG Matthew Blackman - Stifel Operator Welcome to the Globus Medical's Fourth Quarter and Full Year 2024 Earnings Call. This time, all lines will be on mute and a Q&A session will be held after the prepared remarks.
Globus Medical (GMED) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Globus Medical (GMED) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Globus Medical (GMED) Q4 Earnings and Revenues Top Estimates
Globus Medical (GMED) came out with quarterly earnings of $0.84 per share, beating the Zacks Consensus Estimate of $0.76 per share. This compares to earnings of $0.60 per share a year ago.
Globus Medical: Q4 Revenue Tops Forecast
Medical technologies specialist Globus Medical (GMED 0.04%) reported impressive results for the fourth quarter of 2024 on Thursday, Feb. 20. The highlights included adjusted earnings per share (EPS) of $0.84, exceeding the consensus forecast of $0.75, along with revenue that reached $657.3 million, topping expectations by $12.3 million.
Globus Medical (GMED) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Get a deeper insight into the potential performance of Globus Medical (GMED) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Globus Medical (GMED) Reports Next Week: Wall Street Expects Earnings Growth
Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Globus Medical (GMED) is a Top-Ranked Growth Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
